130 related articles for article (PubMed ID: 18275521)
1. Adalimumab: a new alternative biologic agent for chronic plaque psoriasis.
Ormerod AD
Br J Dermatol; 2008 Mar; 158(3):435-6. PubMed ID: 18275521
[No Abstract] [Full Text] [Related]
2. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
Revicki D; Willian MK; Saurat JH; Papp KA; Ortonne JP; Sexton C; Camez A
Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
[TBL] [Abstract][Full Text] [Related]
3. Rapid remission of psoriasis with reversible leucopenia after two injections with adalimumab.
Jordan J; Bieber T; Wilsmann-Theis D
Clin Exp Dermatol; 2009 Dec; 34(8):e1004-5. PubMed ID: 20055818
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept.
Bissonnette R; Bolduc C; Poulin Y; Guenther L; Lynde CW; Maari C
J Am Acad Dermatol; 2010 Aug; 63(2):228-34. PubMed ID: 20494479
[TBL] [Abstract][Full Text] [Related]
5. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.
Strober BE; Poulin Y; Kerdel FA; Langley RG; Gu Y; Gupta SR; Okun MM; Papp KA
J Am Acad Dermatol; 2011 Apr; 64(4):671-81. PubMed ID: 21414495
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of adalimumab in plaque psoriasis: experience on 28 patients.
Ardigò M; Giuliani A; de Felice C; Mastroianni A; Berardesca E
J Drugs Dermatol; 2008 Oct; 7(10):935-9. PubMed ID: 19112756
[TBL] [Abstract][Full Text] [Related]
7. Successful adalimumab desensitization after generalized urticaria and rhinitis.
Rodríguez-Jiménez B; Domínguez-Ortega J; González-Herrada C; Kindelan-Recarte C; Loribo-Bueno P; Garrido-Peño N
J Investig Allergol Clin Immunol; 2009; 19(3):246-7. PubMed ID: 19610276
[No Abstract] [Full Text] [Related]
8. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab.
Yawalkar N; Hunger RE
Dermatology; 2009; 218(1):79-83. PubMed ID: 18974629
[No Abstract] [Full Text] [Related]
9. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
[TBL] [Abstract][Full Text] [Related]
13. Dose-creep of Infliximab during psoriasis treatment: an observational study.
Mehren CR; Gniadecki R
Acta Derm Venereol; 2012 Jul; 92(4):355-7. PubMed ID: 22042041
[No Abstract] [Full Text] [Related]
14. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.
Reich K; Signorovitch J; Ramakrishnan K; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
J Am Acad Dermatol; 2010 Dec; 63(6):1011-8. PubMed ID: 20933301
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF agents for the treatment of psoriasis.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
[TBL] [Abstract][Full Text] [Related]
16. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
Noda S; Mizuno K; Adachi M
J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
[TBL] [Abstract][Full Text] [Related]
17. Treatment of psoriasis with adalimumab.
Pitarch G; Sanchez-Carazo JL; Mahiques L; Perez-Ferriols MA; Fortea JM
Clin Exp Dermatol; 2007 Jan; 32(1):18-22. PubMed ID: 17305904
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of adalimumab].
Casado M
Actas Dermosifiliogr; 2008 Feb; 99 Suppl 3():10-4. PubMed ID: 18680685
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.
Nelson AA; Pearce DJ; Fleischer AB; Balkrishnan R; Feldman SR
J Am Acad Dermatol; 2008 Jan; 58(1):125-35. PubMed ID: 17996329
[TBL] [Abstract][Full Text] [Related]
20. [Practical management of adalimumab].
Avalos P; Camacho FM
Actas Dermosifiliogr; 2008 Feb; 99 Suppl 3():25-7. PubMed ID: 18680687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
